Clinical Trials Logo

Acute Optic Neuritis clinical trials

View clinical trials related to Acute Optic Neuritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02833142 Completed - Multiple Sclerosis Clinical Trials

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Start date: July 2016
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers. Secondary objectives are: To assess the safety and tolerability of BIIB033-A and BIIB033-B; To assess the secondary PK parameters of BIIB033-A and BIIB033-B; To assess the immunogenicity of BIIB033-A and BIIB033-B.

NCT ID: NCT02657915 Completed - Clinical trials for Acute Optic Neuritis

Long-Term Assessment of Remyelinating Therapy

RENEWED
Start date: March 10, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess full-field visual evoked potential (FF-VEP) latency in subjects who were enrolled in Study NCT01721161 2 years (+ up to 12 months) after the last study visit. The secondary objective is to assess clinical progression and severity of central nervous system (CNS) demyelinating disease in subjects who were enrolled in Study NCT01721161 2 years (+ up to 12 months) after the last study visit. Intervention was administered in the previous study. The participants, investigator and outcome assessors remain blinded in this follow-up study.

NCT ID: NCT01721161 Completed - Clinical trials for Acute Optic Neuritis

215ON201 BIIB033 In Acute Optic Neuritis (AON)

RENEW
Start date: December 2012
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with their first episode of unilateral Acute Optic Neuritis (AON). The secondary objective of this study in this study population is to assess the safety, tolerability, and pharmacokinetics (PK) of BIIB033.